Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) EBITDA Margin (2016 - 2022)

Aptevo Therapeutics' EBITDA Margin history spans 8 years, with the latest figure at 180.19% for Q1 2022.

  • For Q1 2022, EBITDA Margin rose 10432.0% year-over-year to 180.19%; the TTM value through Dec 2022 reached 919.75%, down 74565.0%, while the annual FY2022 figure was 919.75%, 74565.0% down from the prior year.
  • EBITDA Margin for Q1 2022 was 180.19% at Aptevo Therapeutics, down from 110.23% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 87.88% in Q4 2019 and bottomed at 1439.11% in Q2 2020.
  • The 5-year median for EBITDA Margin is 182.3% (2018), against an average of 317.06%.
  • The largest annual shift saw EBITDA Margin plummeted -126389bps in 2020 before it skyrocketed 125512bps in 2021.
  • A 5-year view of EBITDA Margin shows it stood at 653.73% in 2018, then surged by 87bps to 87.88% in 2019, then tumbled by -227bps to 287.36% in 2020, then surged by 62bps to 110.23% in 2021, then crashed by -63bps to 180.19% in 2022.
  • Per Business Quant, the three most recent readings for APVO's EBITDA Margin are 180.19% (Q1 2022), 110.23% (Q4 2021), and 153.42% (Q3 2021).